266 related articles for article (PubMed ID: 24915569)
1. Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
Maekawa N; Konnai S; Ikebuchi R; Okagawa T; Adachi M; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Murata S; Ohashi K
PLoS One; 2014; 9(6):e98415. PubMed ID: 24915569
[TBL] [Abstract][Full Text] [Related]
2. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
Choi JW; Withers SS; Chang H; Spanier JA; De La Trinidad VL; Panesar H; Fife BT; Sciammas R; Sparger EE; Moore PF; Kent MS; Rebhun RB; McSorley SJ
PLoS One; 2020; 15(7):e0235518. PubMed ID: 32614928
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
4. PD-1 expression by canine T cells and functional effects of PD-1 blockade.
Coy J; Caldwell A; Chow L; Guth A; Dow S
Vet Comp Oncol; 2017 Dec; 15(4):1487-1502. PubMed ID: 28120417
[TBL] [Abstract][Full Text] [Related]
5. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Ikebuchi R; Konnai S; Shirai T; Sunden Y; Murata S; Onuma M; Ohashi K
Vet Res; 2011 Sep; 42(1):103. PubMed ID: 21943148
[TBL] [Abstract][Full Text] [Related]
6. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.
Goto S; Konnai S; Okagawa T; Nishimori A; Maekawa N; Gondaira S; Higuchi H; Koiwa M; Tajima M; Kohara J; Ogasawara S; Kato Y; Suzuki Y; Murata S; Ohashi K
Immun Inflamm Dis; 2017 Sep; 5(3):355-363. PubMed ID: 28544524
[TBL] [Abstract][Full Text] [Related]
7. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
8. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.
Tzeng HT; Tsai HF; Liao HJ; Lin YJ; Chen L; Chen PJ; Hsu PN
PLoS One; 2012; 7(6):e39179. PubMed ID: 22761734
[TBL] [Abstract][Full Text] [Related]
10. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
[TBL] [Abstract][Full Text] [Related]
11. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
14. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of bovine programmed death-ligand 2.
Nishimori A; Konnai S; Ikebuchi R; Okagawa T; Nakajima C; Suzuki Y; Mingala CN; Murata S; Ohashi K
Microbiol Immunol; 2014 Jul; 58(7):388-97. PubMed ID: 24845976
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
19. Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes.
Ikebuchi R; Konnai S; Okagawa T; Yokoyama K; Nakajima C; Suzuki Y; Murata S; Ohashi K
Immunology; 2014 Aug; 142(4):551-61. PubMed ID: 24405267
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
